Klinger, Mark
Adaptive Biotechnologies (United States)
4 papers on CoChat
Most cited papers
- Verified
Multiple early factors anticipate post-acute COVID-19 sequelae
Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., et al. (2022) · Cell
Long-Term Effects of COVID-19COVID-19 Clinical Research Studies
Cited by 1,156
- Verified
Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire
Emerson, R. O., DeWitt, W. S., Vignali, M., Gravley, J., Hu, J. K., Osborne, E. J., Desmarais, C., Klinger, M., Carlson, C. S., Hansen, J. A., et al. (2017) · Nature Genetics
T-cell and B-cell ImmunologyCytomegalovirus and herpesvirus research
Cited by 532
- Verified
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L. (2014) · Science Translational Medicine
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 383
- Verified
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
Oh, D. Y., Cham, J., Zhang, L., Fong, G., Kwek, S. S., Klinger, M., Faham, M., & Fong, L. (2017) · Cancer Research
Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology
Cited by 236
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free